|[October 24, 2013]
Research and Markets: Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/ms89m3/type_2_diabetes)
has announced the addition of the "Type
2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm
and Intensified Competition Expected to Drive Growth by 2019"
report to their offering.
Type 2 Diabetes Market to Grow Significantly, While Remaining Highly
The global type 2 diabetes market is expected to grow from $20.4 billion
in 2012 to $38.8 billion by 2019, at a CAGR of 10.2%, forecasts business
intelligence provider GBI Research.
According to a new report, the US currently has the highest market
share, which will rise from $12.7 billion in 2012 to $27.2 billion by
2019, at a CAGR of 11.6%, followed by the top five EU markets (UK,
France, Germany, Italy and Spain), which will grow from $4.5 billion to
$7.1 billion, at a CAGR of 6.8%.
This increase is due to the anticipated approval of products in
relatively novel treatment classes, such as GLP-1 agonists, DPP-4 and
SGLT-2 inhibitors. Should these expensive drug classes capture
substantial market shares, this would be expected to result in an even
more robut level of market growth.
Furthermore, due to the increase in the number of obesity cases and with
people living longer, the prevalence of type 2 diabetes is also expected
Associate Analyst Dominic Trewartha says: The strong forecast for the
type 2 diabetes market is reliant upon the ability of late-stage
pipeline drugs, such as gemigliptin, to reach expectations created by
promising clinical trial results, and of newly marketed products
including Nesina and Tradjenta to capture a significant share of the
market. In order to do this, they will need to balance clinical efficacy
with safety and tolerability profiles.
However, the sulfonylureas and metformin classes, both widely used among
type 2 diabetes patients, are strongly penetrated by generic and
low-cost products, presenting a potential major barrier to the market.
This report provides an in-depth analysis of major glucose-lowering
drugs for type 2 diabetes, including analyses of their safety, efficacy,
treatment patterns, strengths/weaknesses and overall commercial
prospects. It includes a heat map comparing major drugs in terms of
safety, efficacy and dosing parameters.
This report was built using data and information sourced from
proprietary databases, primary and secondary research, and in-house
analysis conducted by a team of industry experts.
Key Topics Covered
1 Table of Contents
3 Key Marketed Products
4 Pipeline for Type 2 Diabetes
5 Market Forecast to 2019
6 Deals and Strategic Consolidations
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Byetta And Bydureon
- Daiichi Sankyo
- Merck & Co
- Mitsubishi (News - Alert) Tanabe
- Novo Nordisk
- Takeda Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/ms89m3/type_2_diabetes.
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]